Manejo de las toxicidades inmunomediadas por fármacos anti-PD-1/PD-L1

Abstract

The era of immunotherapy has changed the prognosis and quality of life of a large number of patients with lung neoplasms. In general, the treatment of choice has become immunotherapy associated with chemotherapy in multiple scenarios. However, with their emergence, new toxicities have arisen that require rapid identification to achieve optimal control because, although infrequent, they can be life-threatening. Usually, starting treatment with oral or intravenous corticotherapy will be proposed and, depending on the severity of the symptoms, hospitalization and the temporary or definitive suspension of immunotherapy will be considered. In refractory cases, the use of immunomodulatory drugs may be necessary. This protocol aims to summarize the characteristics and general management of these adverse effects.